A kind of acetyl-ornithine deacetylase mutant and its application

By introducing acetylornithine deacetylase mutant into E. coli, the problem of low lysine production efficiency in the prior art was solved, and a significant increase in lysine yield and accumulation amount was achieved.

CN116179522BActive Publication Date: 2024-11-01JILIN MEIHUA AMINO ACID CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211378047.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-11-04
Publication Date
2024-11-01
Estimated Expiration
2042-11-04

AI Technical Summary

Technical Problem

The prior art has not yet found that genes or enzyme changes in the arginine metabolism pathway have an effect on lysine synthesis, resulting in low lysine production efficiency.

Method used

By introducing acetylornithine deacetylase mutant, specifically mutating its proline at position 85 to serine orthreonine, the gene encoding the mutant and expressing it in E. coli, to increase lysine synthesis efficiency.

Benefits of technology

It significantly increases the yield and accumulation of lysine, improves the conversion rate, and has a more significant impact especially on strains with low production levels.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention proposes an acetylornithine deacetylase mutant and its application, belonging to the field of genetic engineering technology. The acetylornithine deacetylase variant has a proline mutation at the 85th position of its amino acid sequence to a serine, and its amino acid sequence is as shown in SEQ ID NO.1. Or the acetylornithine deacetylase variant has a proline mutation at the 85th position of its amino acid sequence to a threonine, and its amino acid sequence is as shown in SEQ ID NO.3. The Escherichia coli carrying the acetylornithine deacetylase variant is applied to the fermentation production of lysine, and its lysine yield is significantly improved. The acetylornithine deacetylase variants 1 and 2 are applied to the fermentation production of lysine, and their lysine accumulation and conversion rate are significantly improved compared with the starting bacteria, and have positive effects on different starting bacteria.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of genetic engineering, and in particular to an acetyl-ornithine deacetylase mutant and application thereof. Background Art

[0002] Escherichia coli is a Gram-negative bacterium with the advantages of fast growth, clear background, and mature metabolic engineering methods. In view of this, Escherichia coli is widely used in the field of industrial fermentation and can be used to produce L-amino acids, nucleotides and other organic acids. For the production of L-amino acids, including lysine, threonine, tryptophan and valine, Escherichia coli is a very good base bacteria.

[0003] Lysine is the second largest amino acid produced in the world and is widely used in animal feed, medicine and food industries. About 90% of it is used in the feed industry and 10% in the food and medicine industries. As an animal feed additive, lysine can help the body absorb other amino acids, thereby improving feed quality.

[0004] From a biochemical perspective, lysine belongs to the aspartate family of amino acids. Escherichia coli synthesizes lysine, starting from aspartate, and obtains lysine through multiple steps of enzyme-catalyzed reactions. Aspartate is the direct precursor for lysine synthesis, and the enhancement of the former supply can effectively increase the yield of lysine. A key enzyme that catalyzes the production of aspartate in Enterobacter is aspartate ammonium ion lyase, which is encoded by the argE gene. The enzyme can aminate fumarate, an intermediate product of the TCA cycle, into aspartate in one step. There are many ways to improve the expression efficiency of aspartate ammonium ion lyase in existing studies, including multiple copies of the gene, or enhanced expression of the promoter, or the introduction of amino acid mutations at specific positions of the enzyme, resulting in changes in the catalytic activity or catalytic efficiency of the enzyme.

[0005] In addition, there are a large number of reports on improving the efficiency of lysine synthesis, such as increasing the expression level of related enzymes by strengthening the related genes of the lysine synthesis pathway. Or optimizing the expression level of related genes of central carbon metabolism to redistribute the carbon flow ratio. Or strengthening the supply of reducing cofactors to remove the related rate-limiting bottleneck. In addition, there are also literature reports that improving the regulatory mechanism of cells by interfering with global regulation or stress response can also have a positive effect on amino acid synthesis.

[0006] However, there has been no relevant report so far that changes in genes or enzymes in the arginine metabolic pathway have an impact on the synthesis of lysine. The inventors of the present invention have found in many years of research and practice that acetyl-ornithine deacetylase related to arginine metabolism can subtly regulate the synthesis of lysine. Some specific variants of the enzyme can significantly improve the efficiency of lysine synthesis by Enterobacteriaceae, thereby completing the present invention. Summary of the invention

[0007] The object of the present invention is to provide an acetyl-ornithine deacetylase variant and the fermentation application of a recombinant strain carrying the variant in view of the deficiencies of the prior art.

[0008] The technical solution of the present invention is achieved in this way:

[0009] The present invention provides an acetylornithine deacetylase mutant, wherein the 85th proline of the acetylornithine deacetylase variant is mutated to serine, and the amino acid sequence thereof is as shown in SEQ ID NO.1.

[0010] The present invention further protects the gene encoding the above-mentioned acetyl-ornithine deacetylase mutant, whose nucleotide sequence is as shown in SEQ ID NO.2.

[0011] The present invention further protects an acetylornithine deacetylase mutant, wherein the proline at position 85 of the acetylornithine deacetylase variant is mutated to threonine, and the amino acid sequence thereof is as shown in SEQ ID NO.3.

[0012] The present invention further protects a gene encoding the above-mentioned acetyl-ornithine deacetylase mutant, whose nucleotide sequence is shown in SEQ ID NO.4.

[0013] The present invention further protects an engineered bacterium comprising the gene of the acetyl-ornithine deacetylase mutant.

[0014] As a further preference of the present invention, the engineered bacteria is Escherichia coli.

[0015] As a further preferred embodiment of the present invention, the engineered bacteria is the lysine-producing strain MHZ-0914, with a preservation number of CGMCC No.22648.

[0016] The present invention further protects the use of the above-mentioned engineering bacteria in producing lysine.

[0017] The invention has the following beneficial effects: the lysine yield is significantly improved when the Escherichia coli carrying the acetyl-ornithine deacetylase variants are applied to the fermentation production of lysine. The acetyl-ornithine deacetylase variants 1 and 2 are applied to the fermentation production of lysine, and the lysine accumulation and conversion rate are significantly improved compared with the starting bacteria, and the positive effects are achieved on different starting bacteria. DETAILED DESCRIPTION

[0018] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0019] The lysine-producing strain MHZ-0914 has a deposit number of CGMCC No. 22648. It was deposited on June 1, 2021 at the General Microbiology Center of the China Culture Collection Administration, located at the Institute of Microbiology, Chinese Academy of Sciences, No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing. It is classified and named: Escherichia coli.

[0020] The model bacteria MG1655 was MG1655 E. coli Strain, purchased from Shanghai Zeye Biotechnology Co., Ltd.

[0021] Terminology explanation:

[0022] The gene names involved in the present invention are explained as follows: Acetylornithinedeacetylase: acetylornithine deacetylase, abbreviated as AO. argE: acetylornithine deacetylase encoding gene.

[0023] The primer sequence information used in the following examples is shown in Table 1:

[0024] Table 1. Primer sequence information

[0025] Primer Name Sequence (5’-3’) SEQ ID pTF-argE-sgRNA-F tcctaggtataatactagtgttcaggacttcatcacatggttttagagctagaaatagc SEQ ID NO.5 pTF-argE-sgRNA-R actagtattatacctaggactgagctagctgtcaag SEQ ID NO.6 argE-P85-UF cattgctttgcgctgaaaca SEQ ID NO.7 argE-P85S-UR ggggcataccgatacggtgagttttgatgacggtcgctgg SEQ ID NO.8 argE-P85S-DF ccagcgaccgtcatcaaaactcaccgtatcggtatgcccc SEQ ID NO.9 argE-P85-DR ggttagaagcgtcgccaccg SEQ ID NO.10 argE-P85T-UR ggggcataccgatacggtgacttttgatgacggtcgctgg SEQ ID NO.11 argE-P85T-DF ggggcataccgatacggtgacttttgatgacggtcgctgg SEQ ID NO.12 argE-P85-F1 ctaaactcgctgatatccga SEQ ID NO.13 argE-P85-R1 tcatagccagggatcggcgg SEQ ID NO.14

[0026] If no specific techniques or conditions are specified in the examples, the techniques or conditions described in the literature in the field or the product instructions are used. If no manufacturer is specified for the reagents or instruments used, they are all conventional products that can be purchased through regular channels.

[0027] Example 1 Introduction of acetyl-ornithine deacetylase variant 1 into model bacteria MG1655

[0028] (1) Construction of pTargetF-N20-argE(P85S) plasmid and Donor DNA

[0029] Step 1: Use pTF-argE-sgRNA-F / pTF-argE-sgRNA-R as primers and plasmid pTargetT as template (see Multigene Editing in the Escherichiacoli Genome via the CRISPR-Cas9 System, Jiang Y, Chen B, et al. Appl. Environ Microbiol, 2015) to amplify the pTF linear plasmid with N20, assemble the linear plasmid at 37°C using the seamless assembly Clone Express kit, and then transform Trans1-T1 competent cells to obtain pTargetF-N20-argE (P85S), and perform PCR identification and sequencing verification;

[0030] Step 2: Using the MG1655 genome as a template, select the argE-P85-UF / argE-P85S-UR primer pair to amplify the upstream homology arm ①, select the argE-P85S-DF / argE-P85-DR primer pair to amplify the downstream homology arm ②, and use ① and ② as templates and select the argE-P85-UF / argE-P85-DR primer pair to amplify the Donor DNA. The role of the Donor DNA is to provide homologous recombination fragments.

[0031] (2) Preparation of competent cells and electroporation

[0032] Step 1: Electroporate the pCas plasmid (see Multigene Editing in the Escherichiacoli Genome via the CRISPR-Cas9 System, Jiang Y, Chen B, et al. Appl. Environ Microbiol, 2015) into the competent cells of the model strain MG1655 (the transformation method and competent cell preparation method are both referred to "Molecular Cloning III").

[0033] Step 2: Pick a single colony and place it in a 5 mL LB tube containing kanamycin and a final concentration of 10 mM arabinose. Cultivate at 30°C, 200 r / min until OD650 reaches 0.4, then prepare electroporation competent cells (refer to "Molecular Cloning III" for the competent cell preparation method).

[0034] Step 3: The pTargetF-N20-argE (P85S) plasmid and Donor DNA constructed in (1) were simultaneously electroporated into competent cells carrying pCas (electroporation conditions: 2.5 kV, 200 Ω, 25 μF), spread on LB plates containing spectinomycin and kanamycin, and cultured at 30°C until single colonies were visible.

[0035] (3) Recombination verification

[0036] Step 1: Use primer pair argE-P85-F1 / argE-P85-R1 to perform colony PCR verification on the above single colony; Step 2: Amplify the strain correctly identified by PCR with primer pair argE-P85-F1 / argE-P85-R1, and send the amplified product for sequencing to verify the integrity of the sequence.

[0037] (4) Elimination of plasmids

[0038] Step 1: Pick a single colony that has been verified by sequencing and inoculate it into a 5 mL LB tube containing kanamycin and a final concentration of 0.5 mM IPTG. After culturing overnight at 30°C, streak it onto an LB plate containing kanamycin.

[0039] Step 2: Pick a single colony and spot it on an LB plate containing kanamycin and spectinomycin and an LB plate containing only kanamycin, and culture it at 30°C overnight. If it cannot grow on the LB plate containing kanamycin and spectinomycin, but grows on the LB plate containing kanamycin, it indicates that the pTargetF-N20 plasmid has been successfully eliminated;

[0040] Step 3: Pick the positive colonies that have successfully eliminated the pTargetF-N20 plasmid, inoculate them into an antibiotic-free LB tube, culture them at 42°C for 8 hours, then streak them onto an LB plate and culture them at 37°C overnight;

[0041] Step 4: Pick a single colony and spot it on an LB plate containing kanamycin and an LB plate without antibiotics. If it cannot grow on the LB plate containing kanamycin but grows on the LB plate without antibiotics, it indicates that the pCas plasmid is lost. The resulting strain is named 1655-argE85S.

[0042] Example 2 Introduction of acetyl-ornithine deacetylase variant 1 into strain MHZ-0914

[0043] The method used in Example 2 is the same as that in Example 1, including the tool plasmid, Doner DNA, competent cell preparation and gene recombination screening method, the difference is the replacement of the target transformed bacteria. The strain finally obtained was named 22648-argE85S.

[0044] Example 3 Introduction of acetyl-ornithine deacetylase variant 2 into model bacteria MG1655

[0045] The construction principle and method were the same as those in Example 1, and a strain containing the target mutation was obtained, in which the 85th amino acid of acetyl-ornithine deacetylase was mutated to threonine. The obtained strain was named 1655-argE85T.

[0046] (1) Construction of pTargetF-N20-argE(P85T) plasmid and Donor DNA

[0047] Step 1: Use pTF-pykA-sgRNA-F / pTF-pykA-sgRNA-R as primers and plasmid pTargetT as template to amplify the pTF linear plasmid with N20, assemble this linear plasmid at 37°C using the seamless assembly Clone Express kit, and then transform Trans1-T1 competent cells to obtain pTargetF-N20-argE (P85T), which is then identified by PCR and verified by sequencing; this plasmid is used to provide the targeting sequence and can be shared with the pTargetF-N20-argE (P85S) plasmid.

[0048] Step 2: Using the MG1655 genome as a template, select the argE-P85-UF / argE-P85T-UR primer pair to amplify the upstream homology arm ①, select the argE-P85T-DF / argE-P85-DR primer pair to amplify the downstream homology arm ②, and use ① and ② as templates and select the argE-P85-UF / argE-P85-DR primer pair to amplify the Donor DNA.

[0049] (2) Preparation of competent cells and electroporation

[0050] Step 1: Prepare competent cells of MG1655 and electroporate the pCas plasmid into the competent cells (the transformation method and competent preparation method refer to "Molecular Cloning III").

[0051] Step 2: Pick a single colony and place it in a 5 mL LB tube containing kanamycin and a final concentration of 10 mM arabinose. Cultivate at 30°C, 200 r / min until OD650 reaches 0.4, then prepare electroporation competent cells (refer to "Molecular Cloning III" for the competent cell preparation method).

[0052] Step 3: The pTargetF-N20-argE (P85T) plasmid and Donor DNA constructed in (1) were simultaneously electroporated into competent cells carrying pCas (electroporation conditions: 2.5 kV, 200 Ω, 25 μF), spread on LB plates containing spectinomycin and kanamycin, and cultured at 30°C until single colonies were visible.

[0053] (3) Recombination verification

[0054] Step 1: Use primer pair argE-P85-F1 / argE-P85-R1 to perform colony PCR verification on the above single colony; Step 2: Amplify the strain correctly identified by PCR with primer pair argE-P85-F1 / argE-P85-R1, and send the amplified product for sequencing to verify the integrity of the sequence.

[0055] (4) Elimination of plasmids

[0056] Step 1: Pick a single colony that has been verified by sequencing and inoculate it into a 5 mL LB tube containing kanamycin and a final concentration of 0.5 mM IPTG. After culturing overnight at 30°C, streak it onto an LB plate containing kanamycin.

[0057] Step 2: Pick a single colony and spot it on an LB plate containing kanamycin and spectinomycin and an LB plate containing only kanamycin, and culture it at 30°C overnight. If it cannot grow on the LB plate containing kanamycin and spectinomycin, but grows on the LB plate containing kanamycin, it indicates that the pTargetF-N20 plasmid has been lost;

[0058] Step 3: Pick the positive colonies with pTargetF-N20 plasmid loss, inoculate them into antibiotic-free LB tubes, culture them at 42°C for 8 hours, then streak them onto LB plates and culture them at 37°C overnight;

[0059] Step 4: Pick a single colony and spot it on an LB plate containing kanamycin and an LB plate without antibiotics. If it cannot grow on the LB plate containing kanamycin but grows on the LB plate without antibiotics, it indicates that the pCas plasmid is lost. The resulting strain is named 1655-argE85T.

[0060] Example 4 Introduction of acetyl-ornithine deacetylase variant 2 into strain MHZ-0914

[0061] The method used in Example 4 is the same as that in Example 3, including the tool plasmid, Doner DNA, competent cell preparation and gene recombination screening method, the difference is the replacement of the target transformed bacteria. The strain finally obtained was named 22648-argE85T.

[0062] Example 5 Performance of the recombinant strain in producing lysine

[0063] Culture medium:

[0064] Activation medium: peptone 10g / L, NaCl 10g / L, yeast powder 5g / L, agar powder 18g / L, adjust pH to 7.0.

[0065] Seed culture medium: glucose 10g / L, ammonium sulfate 4g / L, yeast extract 2.0g / L, potassium dihydrogen phosphate 3g / L, magnesium sulfate heptahydrate 0.4g / L, ferrous sulfate 0.01g / L, manganese sulfate 0.01g / L, pH 7.0.

[0066] Fermentation medium: glucose 50g / L, ammonium sulfate 25g / L, yeast extract 4.0g / L, potassium dihydrogen phosphate 1.6g / L, magnesium sulfate heptahydrate 1.0g / L, ferrous sulfate 0.03g / L, manganese sulfate 0.03g / L, calcium carbonate 25, pH 7.0.

[0067] Performance verification method:

[0068] (1) Seed activation: Take the strain to be verified from the cryopreserved tube, streak it on the seed activation medium, and culture it at 37°C for 12 h;

[0069] (2) Seed culture: Pick activated seeds 1 from the plate and place them in a 500-mL Erlenmeyer flask containing 20 mL of seed culture medium. Culture at 33°C with shaking at 220 rpm for 7 h.

[0070] (3) Fermentation culture: 2 mL of seed solution was inoculated into a 500 mL Erlenmeyer flask containing 20 mL of fermentation medium and cultured at 33 °C and 220 rpm for 12 h.

[0071] (4) Take 2 mL of the fermentation broth and centrifuge (12000 rpm, 2 min), collect the supernatant, and use HPLC to detect the L-lysine content in the fermentation broth of the recombinant bacteria and the control bacteria. The test results are shown in Table 2 below (the data in the table are the average values ​​of three batches).

[0072] Table 2 Performance test of recombinant strains producing lysine

[0073] Strain OD L-Lysine (g / L) Consumed bottom sugar (g / L) Conversion rate % Increase in conversion rate MG1655 13.2 0.2 29 0.7 -- 1655-argE85S 13.3 0.4 31 1.3 85.7% 1655-argE85T 13.4 0.3 25 1.2 71.4% CGMCC No.22648 12.5 10.5 45 23.3 -- 22648-argE85S 12.6 13.0 48 27.1 16.3% 22648-argE85T 12.5 12.3 47 26.2 12.4%

[0074] From the above fermentation results, it can be seen that the strain carrying the acetyl-ornithine deacetylase variant has a significantly higher lysine accumulation than the starting strain. Both variants have positive effects, and have positive effects on different starting strains. Especially on strains with low production levels, the degree of influence is more significant.

[0075] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. An acetyl-ornithine deacetylase mutant, characterized in that: The proline at position 85 of the acetyl-ornithine deacetylase variant is mutated to serine, and its amino acid sequence is as shown in SEQ ID NO.

1.

2. A gene encoding the acetyl-ornithine deacetylase mutant according to claim 1, characterized in that: Its nucleotide sequence is shown in SEQ ID NO.

2.

3. An acetyl-ornithine deacetylase mutant, characterized in that: The proline at position 85 of the acetyl-ornithine deacetylase variant is mutated to threonine, and its amino acid sequence is as shown in SEQ ID NO.

3.

4. A gene encoding the acetylornithine deacetylase mutant according to claim 3, characterized in that: Its nucleotide sequence is shown as SEQ ID NO.

4.

5. An engineered bacterium comprising the gene of the acetylornithine deacetylase mutant according to claim 2 or 4.

6. The engineered bacteria according to claim 5, characterized in that The engineered bacteria is Escherichia coli.

7. The engineered bacteria according to claim 5, characterized in that The engineered bacteria is the lysine production strain MHZ-0914, and its preservation number is CGMCC No.22648.

8. Use of the engineered bacteria according to any one of claims 5 to 7 in producing lysine.